Browse IL6ST

Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Secreted
Domain PF00041 Fibronectin type III domain
PF09240 Interleukin-6 receptor alpha chain
PF06328 Ig-like C2-type domain
Function

Signal-transducing molecule. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize IL6ST for initiating signal transmission. Binding of IL6 to IL6R induces IL6ST homodimerization and formation of a high-affinity receptor complex, which activates Janus kinases (PubMed:2261637). That causes phosphorylation of IL6ST tyrosine residues which in turn activates STAT3 (PubMed:19915009, PubMed:23294003). Mediates signals which regulate immune response, hematopoiesis, pain control and bone metabolism (By similarity). Has a role in embryonic development (By similarity). Does not bind IL6 (PubMed:2261637). Essential for survival of motor and sensory neurons and for differentiation of astrocytes (By similarity). Required for expression of TRPA1 in nociceptive neurons (By similarity). Required for the maintenance of PTH1R expression in the osteoblast lineage and for the stimulation of PTH-induced osteoblast differentiation (By similarity). Required for normal trabecular bone mass and cortical bone composition (By similarity).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001819 positive regulation of cytokine production
GO:0002250 adaptive immune response
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0003012 muscle system process
GO:0003300 cardiac muscle hypertrophy
GO:0005976 polysaccharide metabolic process
GO:0005977 glycogen metabolic process
GO:0006073 cellular glucan metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006112 energy reserve metabolic process
GO:0007159 leukocyte cell-cell adhesion
GO:0007219 Notch signaling pathway
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0008593 regulation of Notch signaling pathway
GO:0010001 glial cell differentiation
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010575 positive regulation of vascular endothelial growth factor production
GO:0010611 regulation of cardiac muscle hypertrophy
GO:0010613 positive regulation of cardiac muscle hypertrophy
GO:0010720 positive regulation of cell development
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0014742 positive regulation of muscle hypertrophy
GO:0014743 regulation of muscle hypertrophy
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0015980 energy derivation by oxidation of organic compounds
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030278 regulation of ossification
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0038154 interleukin-11-mediated signaling pathway
GO:0038165 oncostatin-M-mediated signaling pathway
GO:0042063 gliogenesis
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042508 tyrosine phosphorylation of Stat1 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042510 regulation of tyrosine phosphorylation of Stat1 protein
GO:0042511 positive regulation of tyrosine phosphorylation of Stat1 protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0043500 muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0044042 glucan metabolic process
GO:0044057 regulation of system process
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0045778 positive regulation of ossification
GO:0045785 positive regulation of cell adhesion
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046651 lymphocyte proliferation
GO:0048708 astrocyte differentiation
GO:0048710 regulation of astrocyte differentiation
GO:0048711 positive regulation of astrocyte differentiation
GO:0048861 leukemia inhibitory factor signaling pathway
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050769 positive regulation of neurogenesis
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051962 positive regulation of nervous system development
GO:0070102 interleukin-6-mediated signaling pathway
GO:0070106 interleukin-27-mediated signaling pathway
GO:0070120 ciliary neurotrophic factor-mediated signaling pathway
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070741 response to interleukin-6
GO:0071354 cellular response to interleukin-6
GO:0071593 lymphocyte aggregation
GO:0090257 regulation of muscle system process
GO:0097696 STAT cascade
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
Molecular Function GO:0004896 cytokine receptor activity
GO:0004897 ciliary neurotrophic factor receptor activity
GO:0004915 interleukin-6 receptor activity
GO:0004921 interleukin-11 receptor activity
GO:0004923 leukemia inhibitory factor receptor activity
GO:0004924 oncostatin-M receptor activity
GO:0005126 cytokine receptor binding
GO:0005127 ciliary neurotrophic factor receptor binding
GO:0005138 interleukin-6 receptor binding
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0019970 interleukin-11 binding
GO:0019981 interleukin-6 binding
GO:0030368 interleukin-17 receptor activity
GO:0045509 interleukin-27 receptor activity
GO:0070851 growth factor receptor binding
Cellular Component GO:0005896 interleukin-6 receptor complex
GO:0005900 oncostatin-M receptor complex
GO:0009897 external side of plasma membrane
GO:0030425 dendrite
GO:0043025 neuronal cell body
GO:0043235 receptor complex
GO:0044297 cell body
GO:0070110 ciliary neurotrophic factor receptor complex
GO:0098552 side of membrane
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-6788467: IL-6-type cytokine receptor ligand interactions
R-HSA-168256: Immune System
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-1059683: Interleukin-6 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-112411: MAPK1 (ERK2) activation
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-110056: MAPK3 (ERK1) activation
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL6ST and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL6ST and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21926464MelanomaPromote immunity (infiltration)Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL6ST in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL6ST in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0940.805
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4980.818
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5360.71
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1040.847
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8240.73
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8030.787
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.010.984
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0270.99
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0550.983
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3760.821
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3790.875
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3360.00209
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL6ST in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL6ST. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL6ST. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL6ST.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL6ST. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL6ST expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL6ST and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL6ST
Nameinterleukin 6 signal transducer
Aliases CD130; gp130, oncostatin M receptor; interleukin 6 signal transducer (gp130, oncostatin M receptor); CDW130; ......
Chromosomal Location5q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL6ST collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.